Skip to Content

Vinorelbine Pregnancy and Breastfeeding Warnings

Vinorelbine is also known as: Navelbine

Medically reviewed on August 6, 2018

Vinorelbine Pregnancy Warnings

Vinorelbine has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryotoxicity and fetotoxicity. There are no controlled data in human pregnancy. Vinorelbine should only be given during pregnancy when there are no alternatives and benefit outweighs risk. It is recommended that women of childbearing age be advised to avoid becoming pregnant while receiving therapy with vinorelbine.

If vinorelbine is used during pregnancy, or if the patient becomes pregnant while receiving the drug, then it is recommended that the patient be made aware of the potential hazard to the fetus.

See references

Vinorelbine Breastfeeding Warnings

There are no data on the excretion of vinorelbine into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to vinorelbine in nursing infants, it is recommended that nursing be discontinued in women who are receiving vinorelbine.

See references

References for pregnancy information

  1. "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome, Research Triangle Pk, NC.

References for breastfeeding information

  1. "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome, Research Triangle Pk, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide